CpG-methylation-based risk score predicts progression in colorectal cancer

Area of Science:

• Oncology
• Genomics
• Cancer Biomarkers

Background:

• Colorectal cancer (CRC) progression risk stratification is crucial for personalized therapy.
• Identifying patients with higher risk of progression enables tailored treatment strategies.

Purpose of the Study:

• To develop a predictor for progression-free interval (PFI) in colorectal cancer patients.
• To identify patients with a truly higher risk of CRC progression for precision therapy.

Main Methods:

• Utilized The Cancer Genome Atlas (TCGA) CRC methylation data to develop a risk score.
• Associated the risk score with progression-free interval (PFI) in the CRC cohort.
• Generated a nomogram integrating the risk score and clinical features for PFI prediction.

Main Results:

• The developed risk score showed a significant association with PFI (p < 0.001).
• The nomogram predicted 3-year and 5-year PFI with AUCs of 0.79 and 0.71, respectively.
• The risk score was based on 23 DNA methylation sites.

Conclusions:

• A risk score derived from 23 DNA methylation sites can predict CRC progression.
• This risk score may enhance the prediction of progression in clinical practice.
• The findings support individualized approaches to precision therapy for colorectal cancer.